Compare Stocks → Protect Yourself While There’s Still Time … (From Weiss Ratings) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:SRNE Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeSRNESorrento Therapeutics$0.01-42.2%$0.02$0.00▼$0.42$7.55M2.25482,392 shs54,423 shs(Almost) Everything You Need To Know About The EV MarketClick the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise. Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceSRNESorrento Therapeutics0.00%-28.57%+122.22%-33.33%-93.98%Move Your Money Before May 22 (Ad)The SIX WORDS That Could Destroy America... And The Value of Your Savings. He predicted the dangerous rise of inflation... the death of the 60/40 portfolio... and now, this 40-year market veteran and retirement expert is stepping forward with a new must-see warning for every American. It involves the world's most powerful investors, central bankers, and America's most bitter geopolitical rivals. Here's where Dr. David Eifrig says to move your money immediately.MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationSRNESorrento TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceSRNESorrento TherapeuticsN/AN/AN/AN/ASales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookSRNESorrento Therapeutics$62.84M0.12N/AN/A($0.05) per share-0.27Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateSRNESorrento Therapeutics-$572.84MN/A0.00∞N/AN/AN/AN/A5/13/2024 (Estimated)DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthSRNESorrento TherapeuticsN/AN/AN/AN/AN/AOwnershipInstitutional OwnershipCompanyInstitutional OwnershipSRNESorrento Therapeutics0.02%Insider OwnershipCompanyInsider OwnershipSRNESorrento Therapeutics2.60%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableSRNESorrento Therapeutics799551.28 million536.95 millionOptionableSRNE HeadlinesSourceHeadlineSorrento Therapeutics Inc SRNEmorningstar.com - April 26 at 6:22 AMSorrento Therapeutics (NASDAQ:SRNE) Now Covered by StockNews.comamericanbankingnews.com - April 21 at 2:14 AMSorrento Therapeutics Wins Appeal Over Covid Treatment Remarksnews.bloomberglaw.com - March 27 at 4:18 AMSorrento Therapeutics Wins Appeal Over Covid Treatment Remarksnews.bloomberglaw.com - March 27 at 4:18 AMSorrento Defeats DOJ Effort to Move Bankruptcy Out of Texas (1)news.bloomberglaw.com - March 12 at 6:20 PMJudge Declines to Dismiss Sorrento Therapeutics Bankruptcy Casewsj.com - March 12 at 6:20 PMVirpax Pharmaceuticals Announces Proposed Settlement of Litigation with Sorrento Therapeutics, Inc. and Scilex Pharmaceuticals, Inc.tmcnet.com - February 27 at 9:57 AMVirpax Pharmaceuticals Announces Proposed Settlement of Litigation with Sorrento Therapeutics, Inc. and Scilex Pharmaceuticals, Inc.businesswire.com - February 27 at 7:30 AMSorrento Therapeuticspharmaphorum.com - February 7 at 10:34 AM5 Sanders Cove, Sorrento WA 6020domain.com.au - January 18 at 9:02 AMSorrento Therapeutics, Inc. (0L85.L)finance.yahoo.com - January 9 at 10:46 AMSorrento WA 6020domain.com.au - December 29 at 3:42 PMSorrento Therapeutics Inc SRNEQmorningstar.com - November 5 at 10:27 AM29 Normanby Road Sorrento VIC 3943domain.com.au - October 15 at 5:35 PMSorrento, Italy - Weather Forecasts | Maps | News - Yahoo Weatheryahoo.com - October 14 at 3:34 PM151 Seacrest Drive Sorrento WA 6020domain.com.au - October 10 at 9:09 PMSorrento holiday apartment accommodation with beach/lake nearby, internet access, balcony/terrace and air conholidaylettings.co.uk - October 9 at 7:15 PM9 Sunset Strip Sorrento VIC 3943domain.com.au - September 14 at 9:37 AMCourt rules Virpax CEO Anthony Mack breached his agreement with Sorrento Therapeuticsbizjournals.com - September 7 at 5:29 PM122 Campbell Street Sorrento QLD 4217domain.com.au - August 21 at 3:59 PMSorrento Therapeutics, Inc. Announces Auction for Sale of Scilex Securities and Bankruptcy Court Approval of Stalking Horse Bidfinance.yahoo.com - August 8 at 11:08 AMCheap Flights from Glasgow to Sorrentoskyscanner.net - August 3 at 1:31 PMCheap Flights from Edinburgh to Sorrentoskyscanner.net - July 29 at 11:29 PMCheap Flights from Bucharest to Sorrentoskyscanner.net - July 29 at 1:28 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsSorrento TherapeuticsNASDAQ:SRNESorrento Therapeutics, Inc. engages in the research, development and manufacture of biopharmaceutical products. It focuses on therapies to treat specific stages in the evolution of cancer, from elimination, to equilibrium and escape which include biosimilars, immuno-oncology antibodies, cellular therapy, cell internalizing antibodies, and antibody drug conjugates. It operates through the Sorrento Therapeutics and Scilex segments. The company was founded by Henry H. Ji in 1989 and is headquartered in San Diego, CA. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.